ACTU
$2.69+0.00 (+0.19%)
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is...
Recent News
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt
Key Insights The considerable ownership by private equity firms in Actuate Therapeutics indicates that they...
Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 Data
Actuate Therapeutics (ACTU) said Tuesday it plans to advance elraglusib in Ewing sarcoma and potenti
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%
The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...